Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30964613)

  • 1. Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites.
    Oyaga-Iriarte E; Insausti A; Bueno L; Sayar O; Aldaz A
    J Pharm Pharm Sci; 2019; 22(1):112-121. PubMed ID: 30964613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.
    Yoshida Y; Hashimoto Y; Miyazaki M; Aisu N; Yamada T; Kajitani R; Munechika T; Matsumoto Y; Nagano H; Shimaoka H; Komono A; Sakamoto R; Yoshimatsu G; Yoshimura F; Kiyomi F; Hasegawa S
    Sci Rep; 2020 Feb; 10(1):2711. PubMed ID: 32066801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.
    Lunar N; Etienne-Grimaldi MC; Macaire P; Thomas F; Dalenc F; Ferrero JM; Pivot X; Milano G; Royer B; Schmitt A
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):229-239. PubMed ID: 33386926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
    Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
    Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model.
    Sakai S; Kobuchi S; Ito Y; Sakaeda T
    Cancer Chemother Pharmacol; 2020 May; 85(5):869-880. PubMed ID: 32240335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
    Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
    Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
    Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
    Urien S; Rezaí K; Lokiec F
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
    Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
    J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of the major metabolites of capecitabine.
    Gieschke R; Reigner B; Blesch KS; Steimer JL
    J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.